The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Budesonide orodispersible (Jorveza®) has been accepted for restricted use in the treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age). The restriction limits use to patients unsuccessfully treated with proton pump inhibitors.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.